MK-7162 / Merck (MSD) - LARVOL DELTA

Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) (clinicaltrials.gov) - P1b; N=41; Completed; Sponsor: Merck Sharp & Dohme Corp.; Active, not recruiting ➔ Completed

Clinical • Combination therapy • Trial completion • Neutropenia • Oncology • Solid Tumor

Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) (clinicaltrials.gov) - P1b; N=40; Active, not recruiting; Sponsor: Merck Sharp & Dohme Corp.; Trial completion date: Jan 2021 ➔ Jul 2020; Trial primary completion date: Jan 2021 ➔ Jul 2020

Clinical • Combination therapy • Trial completion date • Trial primary completion date • Neutropenia • Oncology • Solid Tumor

Side-by-side comparison of small molecule IDO1 inhibitors in biochemical and cell-based assays and development of a IDO1-expressing mouse model to evaluate target modulation (AACR-NCI-EORTC 2019) - "Four small molecule inhibitors are currently investigated in phase III (linrodostat/BMS-986205), phase II (epacadostat/INCB024360) or phase I (MK7162 and LY3381916) clinical trials. Treatment of the B16F10-IDO1 model with epacadostat did not result in a reduction of tumor growth, though epacadostat did induce clear changes in Trp and Kyn in both plasma and tumor tissue. Conclusion Our comparative study of the potencies and selectivities of IDO1 inhibitors, as well as our model for measuring in vivo target modulation, helps to identify strengths and weaknesses of current IDO1 inhibitors, and supports the development of new inhibitors."

IO Biomarker • Preclinical

Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002) (clinicaltrials.gov) - P1b; N=40; Active, not recruiting; Sponsor: Merck Sharp & Dohme Corp.; Recruiting ➔ Active, not recruiting

Clinical • Combination therapy • Enrollment closed • PD(L)-1 Biomarker